KZA News: GBM AGILE OPENS TO PAXALISIB IN EUROPE - 31st May 2022, 9:00pm

[annb0t]

SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm in Europe. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)

University Hospital Zurich in Zurich, Switzerland, under the leadership of principal investigator and regional principal investigator of Europe, Dr Michael...

>>> Read more: GBM AGILE OPENS TO PAXALISIB IN EUROPE